All In Biotech

Drug Trial Radar · NCT04675931

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium Falciparum Malaria (KARISMA - KAE609's Role In Severe Malaria)

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

254

Actual

Start

Mar 7, 2022

Primary completion

Jul 24, 2025

Study completion Aug 20, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
Collaborators
Wellcome Trust; European and Developing Countries Clinical Trials Partnership (EDCTP)
First posted
Dec 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria. The study also intended to evaluate clinical treatment success using a novel clinical endpoint for drug development in severe malaria. Severe malaria is a medical emergency and is affecting primarily young children in Africa. Injectable artesunate is the standard of care for the treatment of severe malaria and is highly efficacious. However, the spread of artemisinin-resistance in Plasmodium falciparum in Asian countries poses a threat for future treatment of patients with this life-threatening disease. To mitigate this risk, there is a need for another drug in malaria-endemic countries. Cipargamin treatment results in rapid clearance of parasites, including artemisinin-resistant parasites.

Conditions

  • Severe Malaria

Interventions

  • CipargaminDrug

    Cipargamin, 20 mg or 40 mg, by intravenous administration of solution for injection

  • IV ArtesunateDrug

    Artesunate, 2.4 mg/kg or 3 mg/kg, by intravenous administration of reconstituted solution

  • CoartemDrug

    Oral standard of care (Coartem tablets, dosed per weight, as per label)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum (P. Falciparum) at 12 HoursTime frame: 12 Hours

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Burkina Faso, Burkina Faso

  • Novartis Investigative Site

    Ouagadougou, Burkina Faso

  • Novartis Investigative Site

    Abidjan, Côte d’Ivoire

  • Novartis Investigative Site

    Agboville, Côte d’Ivoire

  • Novartis Investigative Site

    Kinsasha, Democratic Republic of Congo, Democratic Republic of the Congo

  • Novartis Investigative Site

    Siaya, Kenya

  • Novartis Investigative Site

    Manhiça, Maputo Province, Mozambique

  • Novartis Investigative Site

    Kigali, Rwanda

  • Novartis Investigative Site

    Tororo, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.